OpenAlex | Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet

Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet

Work

Year: 2024

Type: article

Abstract: Breast cancer is the most common and the deadliest cancer among women in the world. Treatment options for HER2-positive metastatic breast cancer patients are limited. Trastuzumab deruxtecan (T-DXd), a... more

Source: Anticancer Research

Authors MOTOKAZU SATO, Qinghong Han, Ryosuke Mori, KOHEI MIZUTA, Byung Mo Kang +5 more

Institutions AntiCancer (United States), University of California, San Diego, Yokohama City University

Cites: 48

Cited by: 19

Related to: 10

FWCI: 20.48

Citation percentile (by year/subfield): 99.97

Topic: Cancer Research and Treatments

Subfield: Biotechnology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

Sustainable Development Goal Good health and well-being

Open Access status: hybrid